Is Cardiac Magnetic Resonance Imaging Useful in Chemotherapy Induced Cardiotoxicity
Dr. Baliga's 'Podkasts for Curious Docs'
Release Date: 10/08/2022
๐ Sun, Skin & Science: The Bright Side of Exposure
Dr. Baliga's 'Podkasts for Curious Docs'
โ๏ธ Walking on Sunshine? Rethinking Our Relationship with the Sun! ๐งด๐งฌ New researchโspotlighted in The Economist (Sep 20, 2025)โchallenges old assumptions: Could moderate sun exposure reduce cardiovascular mortality? โค๏ธ๐ From nitric oxide to vitamin D, this FAQ explores the science, nuance, and shifting global guidelines. Letโs talk melanin, mortality, and medicine! ๐๐ก #Sunlight #CardiovascularHealth #TheEconomist #PublicHealth #MedicalEducation
info_outline
๐ซ Cardiogenic Shock Survival: Impellaโs Decade-Long Edge
Dr. Baliga's 'Podkasts for Curious Docs'
๐จ Cardiogenic ShockโA Decade Later The DanGer Shock Trial shows that patients with STEMI and shock treated with the Impella CP microaxial flow pump lived 600 more days over 10 years vs standard care alone. ๐ Mortality: 52.5% vs 68.8% (HR 0.70) ๐ ๏ธ Despite higher adverse events, the survival benefit endured a full decade. ๐ This changes how we think about long-term outcomes in mechanical support. ๐ Time to revisit your shock protocols? #DanGerShock #Impella #CardiogenicShock #STEMI #LongTermOutcomes #NEJM #MCS #Cardiology #SurvivalBenefit #ImpellaCP
info_outline
๐ Genes, Gradients, and Game-Changers: FAQs on Hypertrophic Cardiomyopathy
Dr. Baliga's 'Podkasts for Curious Docs'
๐ง Hypertrophic Cardiomyopathy โ A Masterclass from Eugene Braunwald ๐งฌ ๐ Just published in NEJM (Aug 2025): a sweeping, state-of-the-art review on HCM โ from Teareโs first autopsy to myosin inhibitors, AI diagnostics, and gene therapy. ๐ฅ Clinical insights, historical depth, trial data (EXPLORER-HCM, SEQUOIA-HCM, VALOR-HCM), and future-facing advancesโall distilled into one must-read. ๐ SCD prevention, ๐ซ LVOT obstruction, ๐งช MYBPC3/MYH7 mutations, ๐งฌ proteomics, and more. ๐ Essential reading for cardiologists, geneticists, and...
info_outline
๐ฌ Silence APOC3, Slash Triglycerides, A New Era in Triglyceride Control
Dr. Baliga's 'Podkasts for Curious Docs'
๐จ New NEJM Study on Olezarsen ๐จ In patients with moderate hypertriglyceridemia and elevated cardiovascular risk, monthly subcutaneous olezarsen reduced triglycerides by over 60% at 6 months! ๐๐ฅ โ Significant drops in APOC3, VLDL, remnant & non-HDL cholesterol โ No rise in LDL-C โ Well-tolerated with mild injection-site reactions ๐ฌ APOC3 inhibition emerges as a game-changer in lipidology. ๐ ESSENCEโTIMI 73b Trial | Funded by Ionis Pharmaceuticals #Cardiology #LipidLowering #PrecisionMedicine #NEJM #Olezarsen #TGlowering #CVRisk #TIMI...
info_outline
Dr RR Baliga's Philosophical Discourses: Dogen (Japan, 1200โ1253 CE) โ Founder of Soto Zen
Dr. Baliga's 'Podkasts for Curious Docs'
๐ธ Dลgen Zenji (1200โ1253), founder of the Sลtล Zen school in Japan, taught that true practice lies in zazenโโjust sittingโ ๐งโโ๏ธโwhere enlightenment and practice are inseparable. His Shลbลgenzล continues to inspire mindfulness & presence today. โณโจ #Zen #Mindfulness
info_outline
NSTEMI: ๐ Less Ischemia, Less Reintervention
Dr. Baliga's 'Podkasts for Curious Docs'
๐จ New Evidence in NSTEMI Care! ๐ซ The SLIM Trial shows that FFR-guided complete revascularization during the index procedure in patients with NSTEMI and multivessel disease significantly reduces death, MI, stroke, and repeat PCI compared to culprit-only PCI. ๐ฏ Key win? Fewer revascularizations, better outcomes โ physiology beats anatomy again. ๐ Published in JAMA, presented at #ESC2025 ๐ Read more: https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.16189 #Cardiology #NSTEMI #FFR #InterventionalCardiology #EvidenceBasedMedicine #SLIMTrial
info_outline
Real-World Rx ๐, Real Results ๐: GLP-1 Agents Slash HFpEF Risk
Dr. Baliga's 'Podkasts for Curious Docs'
๐ฅ Practice-Changing Evidence in HFpEF! ๐ฅ In a real-world cohort of 97,000+ patients with obesity & type 2 diabetes, semaglutide and tirzepatide reduced risk of heart failure hospitalization or death by over 40% ๐ โ๏ธ No meaningful difference between the two agents. ๐ง Findings reinforce STEP-HFpEF & SUMMIT trials and highlight GLP-1 therapiesโ expanding role in cardiometabolic HFpEF ๐ซ #Cardiology #HFpEF #GLP1 #Semaglutide #Tirzepatide #T2DM #RealWorldEvidence #JAMA #HeartFailure
info_outline
The AMALFI AF Screening Trial-๐ Atrial Fibrillation Unmasked: A Modest Win for Mailed Monitors
Dr. Baliga's 'Podkasts for Curious Docs'
๐ข Just read the #AMALFI trial in JAMA ๐ฐ โ a landmark remote RCT of AF screening using 14-day ECG patches mailed to older adults at stroke risk ๐ฆ๐ซ. At 2.5 years, the patch group had a modestly higher AF detection rate (6.8% vs 5.4%, p=0.03) and increased anticoagulation use ๐๐ง . Stroke rates were similar โ๏ธ. ๐ฏ Key takeaway: Remote, mail-based AF screening is feasible and nudges diagnosis rates โ but will it move the needle on outcomes? #AFib #StrokePrevention #RemoteMonitoring #ECG #Cardiology #RCT #JAMA #DigitalHealth #Geriatrics ๐ง๐
info_outline
๐ AFib Gone, OAC Gone? ALONE-AF Challenges Lifelong Therapy
Dr. Baliga's 'Podkasts for Curious Docs'
๐จ New Trial Alert ๐จ Can we safely stop anticoagulation after AF ablation? The ALONE-AF Trial ๐ซ suggests yesโin selected patients with no AF recurrence, stopping DOACs reduced major bleeding ๐ without increasing stroke risk ๐ง . ๐ 0.3% vs 2.2% for the composite outcome (P = .02) ๐ Carefully monitored, low-risk patients may benefit most. ๐ Editorial: Recommends shared decision-making ๐ค & individualized rhythm monitoring. ๐ A potential shift in post-ablation care. ๐ #AFib #Anticoagulation #EPTrials #CardioTwitter #StrokePrevention #JAMA...
info_outline
๐ฆ ๐Bugged After the Heartbreak? Does H. pylori Screening After MI Prevent GI Bleeds?
Dr. Baliga's 'Podkasts for Curious Docs'
๐จ New Findings from the HELP-MI Trial! ๐ธ๐ช๐งช Can routine Helicobacter pylori screening during acute myocardial infarction (MI) hospitalization prevent upper gastrointestinal bleeding (UGIB)? ๐ Over 18,000 patients across 35 Swedish hospitals ๐ Result: No significant reduction in UGIB overall (RR 0.90; P=0.18) ๐ BUT: Clear benefit in patients with anemia (RR 0.44โ0.64) and chronic kidney disease (RR 0.75) ๐ง Key Takeaway: Routine screening isnโt broadly warrantedโbut targeted testing in high-risk AMI patients may be the smarter path forward. ๐...
info_outlineDr RR Baliga's 'Got Knowledge Doc?' PodKasts for Physicians| Is Cardiac Magnetic Resonance Imaging Useful in Chemotherapy Induced Cardiotoxicity
- Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis European Heart Journal, Volume 41, Issue 18, 7 May 2020, Pages 1733โ1743,
- Immune checkpoint inhibitor cardiotoxicity: what can we learn from real life data on CMR as a diagnostic tool? European Heart Journal, Volume 41, Issue 18, 7 May 2020, Pages 1744โ1746
- Can Quantitative CMR Tissue Characterization Adequately Identify Cardiotoxicity During Chemotherapy? Impact of Temporal and Observer Variability. JACC Cardiovasc Imaging 2020;13:951-962.